Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland

Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland

Abstract Objective We aimed to evaluate the cost-effectiveness of voretigene neparvovec (VN) compared with standard of care (SoC) for patients with inherited retinal disease (IRD) caused by a biallelic RPE65-mutation. VN is a live, non-replicating adeno-associated virus serotype 2 (AAV2). SoC is bes...

Full description

Bibliographic Details
Main Authors: Arjun Bhadhuri, Daniel Dröschel, Mike Guldimann, Claudia Jetschgo, Judit Banhazi, Matthias Schwenkglenks, C. Simone Sutherland
Format: Article
Language:English
Published: BMC 2022-06-01
Series:BMC Health Services Research
Subjects:
RPE65
Cost effectiveness
Health Economics
Inherited retinal disease
Voretigene neparvovec
Switzerland
Online Access:https://doi.org/10.1186/s12913-022-08211-y

Similar Items

Similar Items